FDA expands Abilify use to schizophrenic teens

11/6/2007 | Wall Street Journal (free content), The · Yahoo!

The FDA has granted expanded approval to Bristol-Myers Squibb's antipsychotic drug Abilify for treatment of schizophrenic adolescents aged 13 to 17. The decision follows a six-week, 13-country study that showed the drug performed significantly better than placebo.

View Full Article in:

Wall Street Journal (free content), The · Yahoo!

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Quality Regulatory Affairs
Cardinal Health
Chicago, IL
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC